Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Niitsu

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Molecular Pharmacology|June 22, 2000
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activityN Niitsu, T Kasukabe, A Yokoyama, et al.
British Journal of Cancer|January 1, 1997
Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96N Niitsu, S Iki, K Muroi, et al.
Leukemia|May 23, 2001
Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphomaN Niitsu, M Okamoto, J Okabe-Kado, et al.
Blood|February 27, 2001
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphomaN Niitsu, J Okabe-Kado, M Okamoto, et al.
Annals of Hematology|March 14, 2003
Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literatureN Niitsu, H Nakamine, M Kohri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2010
Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphomaN Niitsu, M Okamoto, J-I Tamaru, et al.
Blood|July 27, 2000
Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemiaN Niitsu, J Okabe-Kado, M Nakayama, et al.
Cancer Research|March 8, 2000
SN-1, a novel leukemic cell line with t(11;16)(q23;p13): myeloid characteristics and resistance to retinoids and vitamin D3Y Hayashi, Y Honma, N Niitsu, et al.
Leukemia|May 17, 2003
Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphomaN Niitsu, M Okamoto, Y Honma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2011
CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximabK Miyazaki, M Yamaguchi, R Suzuki, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Molecular Pharmacology|June 22, 2000
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activityN Niitsu, T Kasukabe, A Yokoyama, et al.
British Journal of Cancer|January 1, 1997
Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96N Niitsu, S Iki, K Muroi, et al.
Leukemia|May 23, 2001
Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphomaN Niitsu, M Okamoto, J Okabe-Kado, et al.
Blood|February 27, 2001
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphomaN Niitsu, J Okabe-Kado, M Okamoto, et al.
Annals of Hematology|March 14, 2003
Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literatureN Niitsu, H Nakamine, M Kohri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2010
Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphomaN Niitsu, M Okamoto, J-I Tamaru, et al.
Blood|July 27, 2000
Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemiaN Niitsu, J Okabe-Kado, M Nakayama, et al.
Cancer Research|March 8, 2000
SN-1, a novel leukemic cell line with t(11;16)(q23;p13): myeloid characteristics and resistance to retinoids and vitamin D3Y Hayashi, Y Honma, N Niitsu, et al.
Leukemia|May 17, 2003
Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphomaN Niitsu, M Okamoto, Y Honma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2011
CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximabK Miyazaki, M Yamaguchi, R Suzuki, et al.
Pageof 9